Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of brivanib for advanced cancer that cannot be treated in any other way (CA182026)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a drug called brivanib to see if it helps people with advanced cancer.
Cancers need a blood supply to help them grow and survive. Growing cancers can attract new blood vessels. This is called ‘angiogenesis'. Researchers are looking at ways to stop cancers being able to grow these new blood vessels. Drugs that block cancer blood vessel growth are called anti angiogenics.
In this trial, they are looking at an anti angiogenic drug called brivanib (also known as brivanib alaninate or BMS 582664). Brivanib may be able to stop cancer blood vessels growing by blocking 2 growth factors called VEGF and FGF.
The aim of the trial is to find out if brivanib helps people with
Who can enter
You can enter this trial if you
- Have an advanced cancer that cannot be removed with surgery or treated in any other way
- Have at least 1 area of cancer that your doctors can measure
- Are well enough to take part in the trial and have a performance status of 0 or 1
- Have satisfactory blood test results
- Have recovered from the side effects of any other treatment
- Are willing to use reliable contraception during the trial and for 12 weeks afterwards if there is any chance you or your partner could become pregnant
- Are at least 18 years old
You cannot enter this trial if you
- Have cancer that has spread to your brain
- Have cancer in your lungs that is near to a large blood vessel or is causing a space (cavity) to form inside your lung
- Have had any bleeding from your cancer, unless it was a very small amount
- Have had an experimental drug as part of another clinical trial in the last 4 weeks
- Have already had brivanib
- Are having any other type of cancer treatment
- Have had minor surgery in the last week, or major surgery in the last 8 weeks
- Have had radiotherapy in the last 2 weeks
- Have had chemotherapy or biological therapy in the last 3 weeks, or have not recovered from the side effects of earlier treatment
- Have had a drug called bevacizumab in the last 8 weeks
- Have had any sort of blood clot in the last 6 months that needed treatment with drugs to thin the blood
- Have had another cancer apart from non melanoma skin cancer, bladder cancer in situ, cervical cancer in situ, or any other cancer that has been treated successfully and there has been no sign of it (complete
remission) for at least 3 years
- Have problems with wounds or ulcers not healing
- Have had a heart attack or heart pain (angina) that could not be controlled with medication in the last year
- Have heart failure or other heart problems that are a cause for concern
- Have had a stroke
- Have high blood pressure or any other serious medical condition that cannot be controlled with medication
- Cannot swallow or absorb tablets for any reason
- Are known to be allergic to brivanib or similar drugs
- Are pregnant or breastfeeding
This is a phase 2 trial that will recruit about 300 people. At the beginning of the trial, people with different types of cancer including breast cancer could take part, but now it is only recruiting people with ovarian cancer.
Everybody taking part in the trial has brivanib for 12 weeks to begin with. You take up to 4 brivanib tablets every day. You will be asked to keep a diary at home to record when you take your tablets.
After 12 weeks, you have a scan to see if your cancer has got bigger or smaller.
If your cancer has grown in size by a quarter or more, you will stop having brivanib and leave the trial. Your doctor will discuss other treatment options with you.
If your cancer has reduced in size by at least half, you can carry on having brivanib.
If your cancer has not got much bigger, or much smaller, you will be put into 1 of 2 treatment groups by a computer. Neither you nor your doctor can decide which group you are in. This is called randomisation. People in group 1 carry on having brivanib. People in group 2 have dummy (
Neither you nor your doctor will know which group you are in. This is called a ‘double blind trial’. But if your cancer starts getting bigger during this part of the trial, the trial doctors can find out if you are taking brivanib or placebo tablets. If are taking the placebo tablets, you can switch back to having brivanib again.
As long as you don’t have any bad side effects, you can carry on taking brivanib for as long as it helps you.
The trial doctors will get a sample of tissue removed when you had a
They will use these samples to learn more about how brivanib works and what happens to it in the body. They will also look at the DNA in your samples to see how genes affect the way people respond to the drug and the side effects they have.
You will see the trial doctors and have some tests before you start treatment. The tests include
- Physical examination
- Heart trace (
- Heart scan (
- CT scan or MRI scan
- Blood and urine tests
You go to hospital once a week for the first 3 weeks of treatment, and then once every 3 weeks after that. You have blood tests at each visit. You have a CT or MRI scan every 6 weeks during treatment, and an echocardiogram every 3 months.
After you finish treatment, you go back to see the trial doctors and have more blood tests and a scan.
How to join a clinical trial
Professor Stan Kaye
Experimental Cancer Medicine Centre (ECMC)